Transcatheter aortic valve replacement (TAVR) is a new treatment option for patients with severe aortic stenosis (narrowing of the aorta) who are not ideal candidates for traditional open heart surgery. Currently, the TAVR procedure is FDA approved for patients with aortic stenosis who are too sick or are considered to be at high risk for traditional, open aortic valve replacement surgery. This procedure received FDA approval in November 2011 and MUSC became the first hospital in South Carolina to perform TAVR in the spring of 2012.

Request your TAVR evaluation by completing the form on the top of this page.

Hear from a real MUSC TAVR patient

Ninety-one year-old Henry Brawner became the first patient in South Carolina to be treated with TAVR, a new minimally invasive treatment option for aortic valve disease. Today, thanks to his new heart valve, Henry is feeling better than he has in years.